Ratings by Rodman & Renshaw (Tony Butler)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/25/2025 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 1/21/2025 | Atara Biotherapeutics | ATRA | Downgrade | Neutral (Buy) |
6.57 (5.17) |
-21.31% | Details | |
| 12/20/2024 | Atara Biotherapeutics | ATRA | New Coverage | Buy (N/A) |
9.93 (5.17) |
-47.94% | Details | |
| 12/19/2024 | TuHURA Biosciences | HURA | New Coverage | Buy (N/A) |
4.38 (1.50) |
-65.75% | Details | |
| 11/5/2024 | Zenas Biopharma | ZBIO | New Coverage | Buy (N/A) |
19.95 (25.28) |
26.72% | Details | |
| 11/5/2024 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
24.97 (18.47) |
-26.03% | Details | |
| 8/7/2024 | G1 Therapeutics | GTHX | Downgrade | Neutral (Buy) |
4.25 (7.15) |
68.24% | Details | |
| 8/2/2024 | CRISPR Therapeutics | CRSP | New Coverage | Buy (N/A) |
54.85 (56.50) |
3.01% | Details | |
| 6/28/2024 | Mural Oncology | MURA | New Coverage | Buy (N/A) |
3.07 (2.04) |
-33.55% | Details | |
| 6/28/2024 | Leap Therapeutics | LPTX | New Coverage | Buy (N/A) |
1.77 (2.06) |
16.38% | Details | |
| 6/28/2024 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
1.14 (70.70) |
6101.75% | Details |
